ESSENCE trial of Novo Nordisk's GLP-1 drug semaglutide shows efficacy in MASH, setting up filings in the US and Europe next year.

Art, architecture and design news. Criticism and reviews from co-chief art critics Roberta Smith and Holland Cotter and architecture critic Michael Kimmelman.

Discover how time and compounded growth of earnings can help even a modest 401(k) balance grow to a significant sum over 20 years.